Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncologix signs agreement with IUT
Oncologix Tech, a developer of medical device for brachytherapy, has signed an agreement with Institut fur Umwelttechnologien, a German company under which the company is licensing its technical
Oncologix Tech, a developer of medical device for brachytherapy, has signed an agreement with Institut fur Umwelttechnologien, a German company under which the company is licensing its technical
Millennium Pharmaceuticals, a wholly-owned subsidiary of Takeda Pharmaceutical Company, has initiated two Phase II clinical trials of MLN8237. The first trial will examine the molecule in adult patients
The study, conducted by Mladen Korbelik at the BC Cancer Agency in Vancouver, has demonstrated that SL052 increased the potency and effectiveness of immunotherapeutic agents when used in
During the trial, Capstone and its service providers will utilize Dataflow Manager as its central interface to track and manage clinical information for the Phase II study. Using
For the year 2008, GAAP net income was $108.7 million, or $0.96 per diluted share, compared to $78 million, or $0.69 per diluted share, in 2007. Mindray reported
For the year ended December 31, 2008, net income was $7.52 million, or $0.34 per diluted share, compared to $3.26 million, or $0.19 per diluted share, for the
Revenues for the first quarter ended January 31, 2009 were $87.4 million, up 5% from $82.9 million for the first quarter ended January 31, 2008. Steve Dubin, CEO
Exelixis said that the increase in the net loss for the quarter was primarily due to the inclusion in 2007 of the gain of $18.1 million associated with
Arkema, a manufacturer of chemical products, reported for the fourth quarter of 2008 a net loss of €72m, in comparison with a net profit of €18m for the
“We are very pleased to welcome Al to our Supervisory Board,” commented Bernhard Sixt, president and chief executive officer of Agendia. “As we continue to expand our U.S.